S&P 500   3,855.36
DOW   30,960.00
QQQ   328.11
pixel
pixel
S&P 500   3,855.36
DOW   30,960.00
QQQ   328.11
pixel
pixel
S&P 500   3,855.36
DOW   30,960.00
QQQ   328.11
pixel
pixel
S&P 500   3,855.36
DOW   30,960.00
QQQ   328.11
pixel
pixel
Log in
NASDAQ:IDXX

IDEXX Laboratories Competitors

$489.21
-3.65 (-0.74 %)
(As of 01/25/2021 12:00 AM ET)
Add
Compare
Today's Range
$482.09
Now: $489.21
$495.97
50-Day Range
$449.88
MA: $487.82
$513.20
52-Week Range
$168.65
Now: $489.21
$516.86
Volume349,259 shs
Average Volume378,568 shs
Market Capitalization$41.73 billion
P/E Ratio85.23
Dividend YieldN/A
Beta0.88

Competitors

IDEXX Laboratories (NASDAQ:IDXX) Vs. ABT, MDT, SYK, ISRG, BDX, and EW

Should you be buying IDXX stock or one of its competitors? Companies in the sub-industry of "health care equipment" are considered alternatives and competitors to IDEXX Laboratories, including Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Intuitive Surgical (ISRG), Becton, Dickinson and (BDX), and Edwards Lifesciences (EW).

Abbott Laboratories (NYSE:ABT) and IDEXX Laboratories (NASDAQ:IDXX) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, risk, valuation, profitability, earnings, analyst recommendations and institutional ownership.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Abbott Laboratories and IDEXX Laboratories, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Abbott Laboratories121302.75
IDEXX Laboratories00303.00

Abbott Laboratories presently has a consensus price target of $115.6875, suggesting a potential upside of 0.84%. IDEXX Laboratories has a consensus price target of $395.6667, suggesting a potential downside of 19.12%. Given Abbott Laboratories' higher possible upside, analysts plainly believe Abbott Laboratories is more favorable than IDEXX Laboratories.

Profitability

This table compares Abbott Laboratories and IDEXX Laboratories' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Abbott Laboratories10.50%18.19%8.29%
IDEXX Laboratories19.20%198.91%25.75%

Earnings and Valuation

This table compares Abbott Laboratories and IDEXX Laboratories' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Abbott Laboratories$31.90 billion6.37$3.69 billion$3.2435.41
IDEXX Laboratories$2.41 billion17.34$427.72 million$4.89100.04

Abbott Laboratories has higher revenue and earnings than IDEXX Laboratories. Abbott Laboratories is trading at a lower price-to-earnings ratio than IDEXX Laboratories, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Abbott Laboratories has a beta of 0.83, suggesting that its stock price is 17% less volatile than the S&P 500. Comparatively, IDEXX Laboratories has a beta of 0.88, suggesting that its stock price is 12% less volatile than the S&P 500.

Insider & Institutional Ownership

72.6% of Abbott Laboratories shares are held by institutional investors. Comparatively, 85.1% of IDEXX Laboratories shares are held by institutional investors. 1.7% of Abbott Laboratories shares are held by company insiders. Comparatively, 2.5% of IDEXX Laboratories shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

IDEXX Laboratories beats Abbott Laboratories on 10 of the 14 factors compared between the two stocks.

IDEXX Laboratories (NASDAQ:IDXX) and Medtronic (NYSE:MDT) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability and earnings.

Analyst Ratings

This is a summary of current ratings and recommmendations for IDEXX Laboratories and Medtronic, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
IDEXX Laboratories00303.00
Medtronic032012.92

IDEXX Laboratories presently has a consensus target price of $395.6667, suggesting a potential downside of 19.12%. Medtronic has a consensus target price of $122.2963, suggesting a potential upside of 4.62%. Given Medtronic's higher probable upside, analysts plainly believe Medtronic is more favorable than IDEXX Laboratories.

Profitability

This table compares IDEXX Laboratories and Medtronic's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
IDEXX Laboratories19.20%198.91%25.75%
Medtronic12.69%9.71%5.30%

Valuation & Earnings

This table compares IDEXX Laboratories and Medtronic's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IDEXX Laboratories$2.41 billion17.34$427.72 million$4.89100.04
Medtronic$28.91 billion5.44$4.79 billion$4.5925.47

Medtronic has higher revenue and earnings than IDEXX Laboratories. Medtronic is trading at a lower price-to-earnings ratio than IDEXX Laboratories, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

IDEXX Laboratories has a beta of 0.88, meaning that its stock price is 12% less volatile than the S&P 500. Comparatively, Medtronic has a beta of 0.7, meaning that its stock price is 30% less volatile than the S&P 500.

Institutional & Insider Ownership

85.1% of IDEXX Laboratories shares are held by institutional investors. Comparatively, 79.2% of Medtronic shares are held by institutional investors. 2.5% of IDEXX Laboratories shares are held by insiders. Comparatively, 0.5% of Medtronic shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

IDEXX Laboratories beats Medtronic on 10 of the 15 factors compared between the two stocks.

IDEXX Laboratories (NASDAQ:IDXX) and Stryker (NYSE:SYK) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability and earnings.

Analyst Ratings

This is a summary of current ratings and recommmendations for IDEXX Laboratories and Stryker, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
IDEXX Laboratories00303.00
Stryker271412.58

IDEXX Laboratories presently has a consensus target price of $395.6667, suggesting a potential downside of 19.12%. Stryker has a consensus target price of $227.4783, suggesting a potential downside of 5.04%. Given Stryker's higher probable upside, analysts plainly believe Stryker is more favorable than IDEXX Laboratories.

Profitability

This table compares IDEXX Laboratories and Stryker's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
IDEXX Laboratories19.20%198.91%25.75%
Stryker12.35%20.94%8.77%

Valuation & Earnings

This table compares IDEXX Laboratories and Stryker's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IDEXX Laboratories$2.41 billion17.34$427.72 million$4.89100.04
Stryker$14.88 billion6.05$2.08 billion$8.2629.00

Stryker has higher revenue and earnings than IDEXX Laboratories. Stryker is trading at a lower price-to-earnings ratio than IDEXX Laboratories, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

IDEXX Laboratories has a beta of 0.88, meaning that its stock price is 12% less volatile than the S&P 500. Comparatively, Stryker has a beta of 0.87, meaning that its stock price is 13% less volatile than the S&P 500.

Institutional & Insider Ownership

85.1% of IDEXX Laboratories shares are held by institutional investors. Comparatively, 71.5% of Stryker shares are held by institutional investors. 2.5% of IDEXX Laboratories shares are held by insiders. Comparatively, 6.8% of Stryker shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

IDEXX Laboratories beats Stryker on 8 of the 15 factors compared between the two stocks.

IDEXX Laboratories (NASDAQ:IDXX) and Intuitive Surgical (NASDAQ:ISRG) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability and earnings.

Analyst Ratings

This is a summary of current ratings and recommmendations for IDEXX Laboratories and Intuitive Surgical, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
IDEXX Laboratories00303.00
Intuitive Surgical381002.33

IDEXX Laboratories presently has a consensus target price of $395.6667, suggesting a potential downside of 19.12%. Intuitive Surgical has a consensus target price of $736.0588, suggesting a potential downside of 2.12%. Given Intuitive Surgical's higher probable upside, analysts plainly believe Intuitive Surgical is more favorable than IDEXX Laboratories.

Profitability

This table compares IDEXX Laboratories and Intuitive Surgical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
IDEXX Laboratories19.20%198.91%25.75%
Intuitive Surgical24.45%12.08%10.44%

Valuation & Earnings

This table compares IDEXX Laboratories and Intuitive Surgical's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IDEXX Laboratories$2.41 billion17.34$427.72 million$4.89100.04
Intuitive Surgical$4.48 billion19.74$1.38 billion$9.9575.58

Intuitive Surgical has higher revenue and earnings than IDEXX Laboratories. Intuitive Surgical is trading at a lower price-to-earnings ratio than IDEXX Laboratories, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

IDEXX Laboratories has a beta of 0.88, meaning that its stock price is 12% less volatile than the S&P 500. Comparatively, Intuitive Surgical has a beta of 0.98, meaning that its stock price is 2% less volatile than the S&P 500.

Institutional & Insider Ownership

85.1% of IDEXX Laboratories shares are held by institutional investors. Comparatively, 86.5% of Intuitive Surgical shares are held by institutional investors. 2.5% of IDEXX Laboratories shares are held by insiders. Comparatively, 1.6% of Intuitive Surgical shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Intuitive Surgical beats IDEXX Laboratories on 10 of the 14 factors compared between the two stocks.

IDEXX Laboratories (NASDAQ:IDXX) and Becton, Dickinson and (NYSE:BDX) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability and earnings.

Analyst Ratings

This is a summary of current ratings and recommmendations for IDEXX Laboratories and Becton, Dickinson and, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
IDEXX Laboratories00303.00
Becton, Dickinson and07702.50

IDEXX Laboratories presently has a consensus target price of $395.6667, suggesting a potential downside of 19.12%. Becton, Dickinson and has a consensus target price of $279.6667, suggesting a potential upside of 7.46%. Given Becton, Dickinson and's higher probable upside, analysts plainly believe Becton, Dickinson and is more favorable than IDEXX Laboratories.

Profitability

This table compares IDEXX Laboratories and Becton, Dickinson and's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
IDEXX Laboratories19.20%198.91%25.75%
Becton, Dickinson and5.11%13.30%5.60%

Valuation & Earnings

This table compares IDEXX Laboratories and Becton, Dickinson and's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IDEXX Laboratories$2.41 billion17.34$427.72 million$4.89100.04
Becton, Dickinson and$17.12 billion4.42$874 million$10.2025.51

Becton, Dickinson and has higher revenue and earnings than IDEXX Laboratories. Becton, Dickinson and is trading at a lower price-to-earnings ratio than IDEXX Laboratories, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

IDEXX Laboratories has a beta of 0.88, meaning that its stock price is 12% less volatile than the S&P 500. Comparatively, Becton, Dickinson and has a beta of 0.79, meaning that its stock price is 21% less volatile than the S&P 500.

Institutional & Insider Ownership

85.1% of IDEXX Laboratories shares are held by institutional investors. Comparatively, 83.2% of Becton, Dickinson and shares are held by institutional investors. 2.5% of IDEXX Laboratories shares are held by insiders. Comparatively, 0.8% of Becton, Dickinson and shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

IDEXX Laboratories beats Becton, Dickinson and on 8 of the 14 factors compared between the two stocks.

IDEXX Laboratories (NASDAQ:IDXX) and Edwards Lifesciences (NYSE:EW) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability and earnings.

Analyst Ratings

This is a summary of current ratings and recommmendations for IDEXX Laboratories and Edwards Lifesciences, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
IDEXX Laboratories00303.00
Edwards Lifesciences271202.48

IDEXX Laboratories presently has a consensus target price of $395.6667, suggesting a potential downside of 19.12%. Edwards Lifesciences has a consensus target price of $90.8704, suggesting a potential upside of 5.80%. Given Edwards Lifesciences' higher probable upside, analysts plainly believe Edwards Lifesciences is more favorable than IDEXX Laboratories.

Profitability

This table compares IDEXX Laboratories and Edwards Lifesciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
IDEXX Laboratories19.20%198.91%25.75%
Edwards Lifesciences18.18%29.00%18.10%

Valuation & Earnings

This table compares IDEXX Laboratories and Edwards Lifesciences' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IDEXX Laboratories$2.41 billion17.34$427.72 million$4.89100.04
Edwards Lifesciences$4.35 billion12.31$1.05 billion$1.8646.18

Edwards Lifesciences has higher revenue and earnings than IDEXX Laboratories. Edwards Lifesciences is trading at a lower price-to-earnings ratio than IDEXX Laboratories, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

IDEXX Laboratories has a beta of 0.88, meaning that its stock price is 12% less volatile than the S&P 500. Comparatively, Edwards Lifesciences has a beta of 0.97, meaning that its stock price is 3% less volatile than the S&P 500.

Institutional & Insider Ownership

85.1% of IDEXX Laboratories shares are held by institutional investors. Comparatively, 80.9% of Edwards Lifesciences shares are held by institutional investors. 2.5% of IDEXX Laboratories shares are held by insiders. Comparatively, 1.5% of Edwards Lifesciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

IDEXX Laboratories beats Edwards Lifesciences on 9 of the 14 factors compared between the two stocks.


IDEXX Laboratories Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Abbott Laboratories logo
ABT
Abbott Laboratories
2.4$114.72-1.6%$203.33 billion$31.90 billion60.70Upcoming Earnings
Medtronic logo
MDT
Medtronic
2.7$116.90-0.3%$157.35 billion$28.91 billion44.62
Stryker logo
SYK
Stryker
2.0$239.55-0.2%$90.02 billion$14.88 billion51.96Upcoming Earnings
Intuitive Surgical logo
ISRG
Intuitive Surgical
1.7$752.01-1.1%$88.40 billion$4.48 billion85.65Earnings Announcement
Becton, Dickinson and logo
BDX
Becton, Dickinson and
2.0$260.24-0.6%$75.69 billion$17.12 billion95.33Dividend Announcement
News Coverage
Edwards Lifesciences logo
EW
Edwards Lifesciences
1.6$85.89-0.4%$53.53 billion$4.35 billion68.71Upcoming Earnings
Boston Scientific logo
BSX
Boston Scientific
2.2$36.78-0.7%$52.67 billion$10.74 billion14.09
Baxter International logo
BAX
Baxter International
2.3$80.10-0.7%$40.92 billion$11.36 billion45.51
DexCom logo
DXCM
DexCom
1.9$376.39-1.7%$36.14 billion$1.48 billion155.53Insider Selling
ResMed logo
RMD
ResMed
1.4$221.68-2.8%$32.12 billion$2.96 billion47.57Upcoming Earnings
Hologic logo
HOLX
Hologic
1.9$76.34-0.8%$19.62 billion$3.78 billion18.18Upcoming Earnings
Insulet logo
PODD
Insulet
1.3$288.91-0.5%$19.05 billion$738.20 million656.63
Teleflex logo
TFX
Teleflex
2.0$382.14-1.1%$17.80 billion$2.60 billion49.18
STERIS logo
STE
STERIS
2.1$190.41-0.9%$16.25 billion$3.03 billion38.62Upcoming Earnings
Varian Medical Systems logo
VAR
Varian Medical Systems
1.3$175.33-0.1%$16.02 billion$3.17 billion59.84
Abiomed logo
ABMD
Abiomed
1.5$348.32-0.1%$15.74 billion$840.88 million76.55Upcoming Earnings
Masimo logo
MASI
Masimo
1.4$257.09-2.6%$14.15 billion$937.84 million66.78
Hill-Rom logo
HRC
Hill-Rom
2.0$101.16-1.7%$6.71 billion$2.88 billion30.47
Globus Medical logo
GMED
Globus Medical
1.4$64.44-1.4%$6.36 billion$785.37 million70.04
Integra LifeSciences logo
IART
Integra LifeSciences
1.4$69.36-0.1%$5.85 billion$1.52 billion103.52
NuVasive logo
NUVA
NuVasive
1.5$56.80-0.2%$2.91 billion$1.17 billion-258.18
AtriCure logo
ATRC
AtriCure
1.3$58.30-1.3%$2.62 billion$230.81 million-50.70
Integer logo
ITGR
Integer
2.3$78.15-1.2%$2.57 billion$1.26 billion35.52
Cardiovascular Systems logo
CSII
Cardiovascular Systems
1.3$46.51-0.3%$1.87 billion$236.54 million-70.47
Alphatec logo
ATEC
Alphatec
0.8$14.92-0.7%$1.17 billion$113.43 million-13.56
CryoLife logo
CRY
CryoLife
1.5$24.96-1.2%$969.87 million$276.22 million-65.68
Orthofix Medical logo
OFIX
Orthofix Medical
1.2$44.94-2.2%$868.77 million$459.95 million37.45
AngioDynamics logo
ANGO
AngioDynamics
1.6$18.55-1.9%$704.04 million$264.16 million-4.15
Surmodics logo
SRDX
Surmodics
1.5$46.33-1.0%$633.89 million$94.86 million579.13News Coverage
Accuray logo
ARAY
Accuray
2.2$5.08-0.6%$463.67 million$382.93 million36.29Upcoming Earnings
Invacare logo
IVC
Invacare
1.6$9.92-0.1%$341.43 million$927.96 million-8.06
Rockwell Medical logo
RMTI
Rockwell Medical
1.3$1.46-2.7%$136.62 million$61.30 million-3.40
This page was last updated on 1/26/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.